Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-87562761 in Relapsed/Refractory Multiple Myeloma
NCT06604715Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of JNJ-87562761 in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 3 years, Adverse Events at 3 years and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
JNJ-87562761
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06604715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604715.